Peptide questions · Sermorelin

Sermorelin side effects: what studies and users report

Reviewed Evidence: EstablishedPublished by PepVault

The side effects most commonly reported for sermorelin are headache, flushing and dizziness, among 6 the library lists; its evidence in people comes from small studies without a control group and from clinical use.

Its safety note opens: sermorelin was FDA-approved as Geref, a test of the pituitary's growth hormone reserve (1990) and a treatment for growth hormone deficiency in children (1997); its maker stopped selling it in 2008, and the FDA later found it was not withdrawn for reasons of safety or effectiveness.

What is commonly reported with sermorelin

  • Headache
  • Flushing
  • Dizziness
  • Nausea
  • Injection site reaction
  • Water retention

Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.

Each effect, and the other growth hormone compounds the library lists it for
EffectAlso listed for (of 13)
Headache4: Ipamorelin, CJC-1295 with DAC, CJC-1295 no DAC, GHRP-2
Flushing3: Ipamorelin, CJC-1295 with DAC, CJC-1295 no DAC
DizzinessNone: listed for Sermorelin alone
Nausea2: Ipamorelin, Tesamorelin
Injection site reaction4: Tesamorelin, IGF-1 LR3, PEG-MGF, Follistatin-344
Water retention9: Ipamorelin, CJC-1295 with DAC, CJC-1295 no DAC, GHRP-2 and 5 more
A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Track sermorelin in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Which sermorelin side effects the growth hormone group shares

Across the 14 growth hormone compounds in the library, the effects listed most often are water retention (10 of 14), headache (5 of 14), injection site reaction (5 of 14) and fatigue (4 of 14). Sermorelin shares 5 of its 6 listed effects with at least one other growth hormone compound; dizziness is listed for sermorelin alone.

What the sermorelin safety notes say

The library’s safety note

Sermorelin was FDA-approved as Geref, a test of the pituitary's growth hormone reserve (1990) and a treatment for growth hormone deficiency in children (1997); its maker stopped selling it in 2008, and the FDA later found it was not withdrawn for reasons of safety or effectiveness. In its studies it was well tolerated, and the side effects reported most were brief facial flushing and pain where the shot went in. A year of nightly injections in 110 children brought no adverse changes in blood chemistry or hormone tests, no change in fasting glucose and no excess IGF-1. In 11 healthy men aged 64 to 76, six weeks of a 2 mg nightly dose brought no significant side effects and no change in glucose, insulin or lipids. Adult use for energy, sleep or body composition rests on small, short studies like that one, not on long trials. This is published-research reference; review it with your clinician.

The library’s interaction note

No study of how sermorelin interacts with other medicines turns up on PubMed. It works through the pituitary, so what blunts the pituitary's growth hormone response blunts sermorelin too: in one study, people with marked obesity released less than half the growth hormone of lean people after the same GHRH(1-29) dose, and 48 hours of the steroid dexamethasone cut the response by about 85% in healthy men. A growth hormone-releasing peptide works on a different receptor, and given together with GHRH the growth hormone release was larger than the sum of either alone (shown with GHRP-6 in healthy men), which is the idea behind pairing sermorelin with ipamorelin. Discuss all your medicines with your clinician.

These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.

Where the sermorelin reports come from

The library rates the evidence on sermorelin as established: clinical trials or FDA-approved use exist.

Of the library’s 5 research notes on sermorelin, 3 rest on clinical data and 2 on community reports.

So the effects listed for sermorelin come from uncontrolled studies and use in people, not from placebo-controlled trials.

Questions people ask

What are the side effects of sermorelin?

The side effects most commonly reported for sermorelin are headache, flushing and dizziness, among 6 the library lists; its evidence in people comes from small studies without a control group and from clinical use.

Do sermorelin’s side effects come from human studies?

The library rates the evidence on sermorelin as established, and its evidence in people comes from small studies without a control group and from clinical use.

Which sermorelin side effects are its own?

Among the growth hormone compounds, the library lists dizziness for sermorelin alone.

Does sermorelin interact with other medicines?

The library’s interaction note on sermorelin begins: No study of how sermorelin interacts with other medicines turns up on PubMed.

More on sermorelin

Track it in the app

PepVault for iPhone

Track sermorelin in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo